FTC Distorted Actavis Ruling In Generics Dispute, Impax Says
By Bryan Koenig ( October 4, 2019, 7:59 PM EDT) -- Impax Laboratories LLC set the stage for a broad Fifth Circuit fight with the Federal Trade Commission in the generic-drug maker's appeal of the agency's reverse-payment decision, accusing the commission Thursday of creating a "jerry-rigged" test to figure out whether payments made to delay a competitor's generic drug are blatantly illegal....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.